Dexamethasone dose-dependently attenuates docetaxel-induced peripheral neuropathy in breast cancer treatment
- 7 April 2025
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (5) , 1-8
Abstract
Purpose Peripheral neuropathy is one of the most problematic adverse effects of docetaxel. We previously reported that dexamethasone (DEX) prevents taxane-associated acute pain syndrome (T-APS) in a dose-dependent manner, which might be a partial manifestation of chemotherapy-induced peripheral neuropathy (CIPN), in breast cancer treatment. Therefore, this study examined the dose-dependent prophylactic efficacy of DEX against CIPN. Methods Female patients with breast cancer receiving docetaxel-containing treatments (75 mg/m2) were divided into two groups according to DEX dosage on days 2–4; an 8 mg group (n = 56) and a 4 mg group (n = 28) and retrospectively evaluated. The primary endpoint in this study was defined as the development of grade ≥ 2 CIPN during 4 cycles of the treatment. Results The incidence of grade ≥ 2 CIPN was 32.1% in the 4 mg group and 10.7% in the 8 mg group and was significantly lower in the 8 mg group (P = 0.03). The incidence of all-grade CIPN was lower in the 8 mg group than in the control group, although the difference was not statistically significant (P = 0.06). Onset time of all-grade and grade ≥ 2 CIPN in the 8 mg group was significantly delayed compared to that in the 4 mg group (P = 0.003 and 0.01, respectively). Additionally, 8 mg/day of DEX was identified as a preventive factor for all-grade CIPN, although the evaluation of grade ≥ 2 symptoms was not possible. Conclusion Our study found that DEX attenuated docetaxel-induced CIPN in a dose-dependent manner during real-world breast cancer treatment. Further studies are needed to develop better CIPN management strategies.Keywords
This publication has 42 references indexed in Scilit:
- Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathyToxicology, 2012
- A lower dose of docetaxel at 60 mg/m2 could be continued longer for controlling peripheral edema in patients with metastatic breast cancerBreast Cancer, 2011
- Natural History of Paclitaxel-Associated Acute Pain Syndrome: Prospective Cohort Study NCCTG N08C1Journal of Clinical Oncology, 2011
- Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management ApproachClinical Breast Cancer, 2011
- Involvement of Substance P in Peripheral Neuropathy Induced by Paclitaxel but Not OxaliplatinThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Early dexamethasone treatment after implantation of a sciatic-nerve cuff decreases the concentration of substance P in the lumbar spinal cord of rats with neuropathic pain.2007
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Glucocorticoids suppress transcriptional up‐regulation of bradykinin receptors in a murine in vitro model of chronic airway inflammationClinical & Experimental Allergy, 2005
- Glucocorticoids inhibit the bradykinin B2 receptor increase induced by interleukin-1β in human bronchial smooth muscle cellsEuropean Journal of Pharmacology, 1998
- Clinical toxicities encountered with paclitaxel (Taxol).1993